Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Hosted on MSN
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based coronavirus ...
Hosted on MSN
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda. The vaccine was ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results